Alain C. Mita

Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

Andrea B. Apolo, Jeffrey R. Infante, Ani Sarkis Balmanoukian et al. · Journal of Clinical Oncology · 2017 · 582 citations

Medicine, Oncology, Pharmacology +17

LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer

Masoud Tavazoie, Ilana Pollack, Raissa Tanqueco et al. · Cell · 2018 · 481 citations · Full text

Life Sciences, Immunology, Oncology +10

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer

Mary L. Disis, Matthew H. Taylor, Karen Kelly et al. · JAMA Oncology · 2019 · 427 citations · Full text

Medicine, Oncology, Pharmacology +15

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors

Josep Tabernero, Rastislav Bahleda, Rodrigo Dienstmann et al. · Journal of Clinical Oncology · 2015 · 384 citations

Medicine, Pharmacokinetics, Pharmacology +14

Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors

Alain C. Mita, Louis Denis, Eric K. Rowinsky et al. · Clinical Cancer Research · 2009 · 332 citations

Medicine, Oncology, Pharmacology +16